Zanubrutinib vs. Ibrutinib Patient Power Video... - CLL Support

CLL Support

23,323 members40,025 posts

Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD

lankisterguy profile image
lankisterguyVolunteer
13 Replies

In this Patient Power video - Dr. Brown is very clear about the advantages of Zanubrutinib over Ibrutinib - especially for 17p and patients with heart risks.

patientpower.info/chronic-l...?

Watch as Jennifer Brown, MD, PhD, Director, CLL Center, Dana Farber, updates our chronic lymphocytic leukemia (CLL) patients on the latest from the 2022 American Society of Hematology (ASH) Annual Meeting, including the results of the ALPINE study and the new BTK inhibitors.

-

Len

Written by
lankisterguy profile image
lankisterguy
Volunteer
To view profiles and participate in discussions please or .
Read more about...
13 Replies
Chemtrails-USA profile image
Chemtrails-USA

”….will be our new standard of care BTK inhibitor.”

Was the good doctor referring only to high risk, previously treated CLL patients?

- Bobby

lankisterguy profile image
lankisterguyVolunteer in reply toChemtrails-USA

Hi Chemtrails-USA,

I believe she is indicating that the early / young data shows the strongest benefit to those high risk patients. It will take more time to see if the future data and other studies show a strong or moderate benefit to untreated or other genetic profiles.

-

The latest NCCN guidelines recommend Zanubrutinib for all CLL patients - see:

ajmc.com/view/nccn-updates-...

Even though the USA FDA has not approved Zanu for any CLL applications yet.

-

The EU & UK may get there first- see: healthunlocked.com/cllsuppo...

healthunlocked.com/cllsuppo...

Len

Rico49 profile image
Rico49 in reply tolankisterguy

Good morning. Any insight into what's the hold up at FDA in US? Secondly, is it reasonable to assume Zanubrutinib would penetrate the blood brain barrier like acali and ibrutinib? Thank you

lankisterguy profile image
lankisterguyVolunteer in reply toRico49

Wow those questions are way above my pay grade, you may want to ask your CLL expert doctor for those

Rico49 profile image
Rico49 in reply tolankisterguy

Thanks- I just found where it may be approved in Jan 2023??

Thundercat2 profile image
Thundercat2

I needed this today thanks for sharing Len! I think you meant 2022 in your post however not 2002:)

lankisterguy profile image
lankisterguyVolunteer in reply toThundercat2

Thanks for catching that one- Patient Power gets credit for that typo- LOL

Denisguay profile image
Denisguay

2002--?

lankisterguy profile image
lankisterguyVolunteer in reply toDenisguay

Thanks for catching that one- Patient Power gets credit for that typo- LOL

Catnap7 profile image
Catnap7

Thank you very much! 🐈🐈

bennevisplace profile image
bennevisplace

Len, does one have to register for this content? None of the videos work for me.

lankisterguy profile image
lankisterguyVolunteer in reply tobennevisplace

Yes, you need to register- giving your email address to see the videos

bennevisplace profile image
bennevisplace in reply tolankisterguy

Thanks!

Not what you're looking for?

You may also like...

Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD

Advances in Targeted Therapy for R/R CLL (These OncLive presentations are intended for medical...
lankisterguy profile image
Volunteer

CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO

Hi, Just back from a frenetic and fantastic ASH, but still have news to share from ASCO. But first...
bkoffman profile image
CLL CURE Hero

EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor

https://cllsociety.org/2022/08/eha-2022-outcomes-following-treatment-with-a-covalent-btk-and-bcl2-in

BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'

In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
CLLerinOz profile image
Administrator

YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success

I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
AussieNeil profile image
Partner